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Abstract
Background: Tuberculosis (TB) disease is a common opportunistic infection among people living with HIV (PLHIV).
WHO recommends at least 6 months of isoniazid Preventive Therapy (IPT) to reduce the risk of active TB. It is
important to monitor the six-month IPT completion since a suboptimal dose may not protect PLHIV from TB
infection. This study determined the six-month IPT completion and factors associated with six-month IPT completion
among PLHIV aged 15 years or more in Dar es Salaam region, Tanzania.
Methods: Secondary analysis of routine data from PLHIV attending 58 care and treatment clinics in Dar es Salaam
region was used. PLHIV, aged 15 years and above, who screened negative for TB symptoms and initiated IPT from
January, 2013 to June, 2017 were recruited. Modified Poisson regression with robust standard errors was used to
estimate prevalence ratios (PR) and 95% confidence interval (CI) for factors associated with IPT completion. Multilevel
analysis was used to account for health facility random effects in order to estimate adjusted PR (APR) for factors
associated with IPT six-month completion.
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Results: A total of 29,382 PLHIV were initiated IPT, with 21,808 (74%) female. Overall 17,092 (58%) six-month IPT
completion, increasing from 42% (773/1857) in year 2013 to 76% (2929/3856) in 2017. Multilevel multivariable model
accounting for health facilities as clusters, showed PLHIV who were not on ART had 46% lower IPT completion compared
to those were on ART (APR: 0.54: 95%CI: 0.45–0.64). There was 37% lower IPT completion among PLHIV who transferred
from another clinic (APR: 0.63: 95% CI (0.54–0.74) compared to those who did not transfer. PLHIV aged 25–34 years had a
6% lower prevalence of IPT completion as compared to those aged 15 to 24 years (APR:0.94 95%CI:0.89–0.98).
Conclusion: The IPT completion rate in PLHIV increased over time, but there was lower IPT completion in PLHIV who
transferred from other clinics, who were aged 25 to 34 years and those not on ART. Interventions to support IPT in these
groups are urgently needed.
Keywords: IPT completion, HIV, Tuberculosis, Predictors, Tanzania
Background
Tuberculosis (TB) disease is common among people living
with HIV (PLHIV), with the lifetime risk of acquiring dis-
ease 20–37 times higher compared to people who are HIV
negative [1–5]. Tuberculosis co-infection increases the
consequences of the HIV burden and contributes to 30–
40% of deaths among PLHIV in high endemic regions [6–
9]. Globally TB/HIV co-infection is a major public health
concern with more than1 million PLHIV co-infected with
TB in the year 2017 [7, 10], and 78% of those conifected
with TB living in Africa [7]. In Tanzania there were 142,
000 new TB cases in 2018, and 34% of these TB cases
were PLHIV [11–14]. In Tanzania more than 1 million
PLHIV attend care and treatment clinic, and in 96% of all
clinic visits they are screened for TB [15]. The conse-
quences of TB/HIV co-infection is an increase in mortality
among PLHIV, with the worldwide estimate of 300,000
deaths among PLHIV co-infected with TB in 2013 and
400,000 in 2017 [3, 7, 8, 11–14, 16].
Isoniazid is the common name for isonicotinylhydrazide
(INH) and is one of the drugs used for first line treatment
for TB infection [17]. Among PLHIV, INH is also used to
prevent TB infection through the Isoniazid Preventive
Therapy (IPT) intervention [10]. In epidemiological stud-
ies from different countries, IPT has been shown to re-
duce risks of TB incidence occurrence by 33–90% among
HIV infected people [7, 10, 18–27]. WHO recommends
the completion of at least 6 months IPT for the successful
prevention of active tuberculosis among PLHIV [4, 10].
Globally, six-month IPT completion has been reported to
range from 39 to 99% [28–37], and in Tanzania studies re-
ported 65–98% of those who initiated IPT, completed the
6 month treatment course [6, 20, 38–40]. Most epidemio-
logical studies have shown that IPT completion reduces
the risks of mortality among PLHIV [8, 26, 41], decreases
the need for expensive TB treatment needs and lowers the
cost of HIV services. Successful use of IPT will help
Tanzania achieve the sustainable development goals
(SDG) by 2030 and is part of the national strategy to con-
trol TB in Tanzania [6, 7, 42, 43]. However, it shows that
a good number of PLHIV do not complete the full six-
month IPT treatment course and little is known about the
determinants of IPT completion in routine HIV clinics
settings. The iinformation on IPT completion would be
useful to the Ministry of Health, Community Develop-
ment, Gender, Elderly and Children (MOHCDGEC) in
order to plan better interventions to prevent TB in among
PLHIV [14, 20, 38, 44–46]. This study aimed to determine
six-month IPT completion and factors associated with
IPT completion among PLHIV aged 15 years or more in
Dar es Salaam region, Tanzania.
Methods
A cross-section study using secondary analysis of de-
identified routinely collected data from PLHIV attending
HIV services in 58 care and treatment clinics (CTC) was
conducted in Dar es Salaam region. The study retrieved
data from the CTC electronic database, which is used to
record the clinical management of PLHIV attending CTC.
The national TB/HIV and HIV guidelines recommend
that all PLHIV should be screened for TB at every clinic
visit using standard TB screening tools [4]. All PLHIV
aged 15 years or more who screened negative for TB and
who were initiated on IPT between January 2013 and
June 2017 were included in the analysis (Fig. 1).
All subsequent clinic records of those who initiated
IPT were reviewed for six-month IPT completion at
their scheduled monthly visits. The outcome variable,
six-month IPT completion, was defined as the collection
of IPT drugs for the full 6 months following initiation.
The independent variables were sex, age, functional sta-
tus, pregnancy status, marital status, ART status, WHO
clinical stage as well as CD4 count cells/μL at IPT initi-
ation. The study used the records of all patients who
initiated IPT in care and treatment centres (CTC) from
all health facilities in Dar es Salaam region from January,
2013 to June, 2017. Figure 1 shows the total clients en-
rolled in HIV care, and the exclusion for different rea-
sons (Fig. 1).
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Data analysis was performed using STATA version
15.0 (STATA Corp, College station, TX). Descriptive
statistics were summarized using means, standard devi-
ation (SD)) and medians (IQR) for continuous variables;
frequency and proportion for category variables. The
chi-square test was used to compare the differences in
the proportion of completing IPT across the patient
characteristics. A modified Poisson regression model
was used to determine the prevalence ratio (PR) and
95% confidence interval (95% CI) of factors associated
with IPT completion. Multilevel modelling was used to
estimate the independent determinants of IPT comple-
tion, while accounting for the dependency of individuals
within health facilities. Intra class correlation was used
to measure the proportion of variability explained by the
between health facilities variation.
The study involved analysis of unlinked data; hence,
there was no contact with human subjects. Ethics
approval for the study was obtained from the Kiliman-
jaro Christian Medical University college - Research
and Ethical Review Committee in 2018 (KCMUCo-
RERC approval number 2388). Secondary use of the
data from the electronic database was requested and
approved by National Aids Control Program (NACP).
NACP owns the data on behalf of MoHCDGEC. Patient
consent was not required for the analysis of anon-
ymised routine data.
Results
A total of 142,837 PLHIV were registered in CTC in Dar-
es-Salaam in the study period. Of these 2223 (0.2%) had
no record of TB screening. Of 140,614 PLHIV, 124,747
(88.7%) had record of a negative TB screening results. Of
those who screened negative 51,266 (41%) initiated IPT,
but we excluded 6700 (13.1%) who were aged less than 15
years and 15,184 who initiated after 1st June 2017, leaving
a total of 29,382 PLHIV in the analysis (Fig. 1).
The demographic and clinical characteristics of the 29,
382 participants who initiated IPT are shown in Table 1
with 21,808 (74.2%) female, and a mean age of 41.4 years
(standard deviation SD: 10.2) (Table 1.). The majority
28,859 (98.2%) were on ART, and the median CD4
counts was 155 cells/μL (interquartile range (IQR): 48–
260), although a large group 13,687 (46.8%) had CD4
counts less than 100 cells/μL. Majority 28,480 (97.1%)
PLHIV were actively attending clinics and 26,512
(90.3%) were attending in their scheduled appointment
dates (Table 1).
Over the period January 2013 to December 2017, the
overall IPT completion prevalence was 58%, but the IPT
completion increased from 42% in 2013 to 76% in 2017
(Fig. 2).
Univariate analysis accounting for clustering at health
facility level, indicated that the six-month IPT comple-
tion was 50% lower among those who were not on ART
Fig. 1 . Flow chart determining how participants were selected
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Table 1 Demographic and Clinical characteristics of 29,382 Participants Attending HIV Services in Dar es Salaam Region
Variable Frequency % IPT completers N = 17,092(58.2) P-value
Age category
15–24 1454 4.9 818(56.3)
25–34 5216 17.8 2999(57.5)
35–44 11,708 39.9 6771(57.8)
≥45 11,004 37.4 6504(59.1)
Mean (standard deviation) 41.4(±10.2) 41.55(±10.1) 0.053
Sex
Male 7574 25.8 12,702(58.2)
Female 21,808 74.2 4390(57.9) 0.667
Marital status (n = 25,888)
Single 7847 30.3 4414(56.2)
Married/cohabiting 13,401 51.8 7945(59.3)
Divorced/widowed 4640 17.9 2823(60.8) < 0.001
Year of Initiation
2013 1857 6.3 773(41.6)
2014 5169 17.6 2254(43.6)
2015 7754 26.4 3783(48.8)
2016 10,746 36.6 7353(68.4)
2017 (Jan to June only) 3856 13.1 2929(75.9) < 0.001
PLHIV by Health facility ownership
Public 20,272 68.9 10,699(52.8)
Private 9110 31.1 6393(70.2) < 0.001
ART status (n = 29,374)
Not on ART 515 1.8 136(26.4)
On ART 28,859 98.2 16,956(58.7) < 0.001
WHO clinical stage (n = 29,121)
I 5026 17.3 3141(62.5)
II 6758 23.2 4017(59.4)
III 14,910 51.2 8505(57.1)
IV 2427 8.3 1348(55.5) < 0.001
CD4 count in cells/μL (n = 29,249)
< 100 13,687 46.8 8001(58.5)
100–349 9927 33.9 5999(60.4)
≥ 350 5635 19.3 3016(53.5) < 0.001
Median (lower quartile, upper quartile) 155(48, 260)
Visit status (n = 29,337)
Actively attending clinics 28,480 97.1 16,720(58.7)
Missing scheduled appointments 383 1.3 186(48.6)
Transferred to another clinic 474 1.6 174(36.7) < 0.001
Co-medications (n = 10,047)
Cotrimoxazole 7180 71.5 4160(57.9)
Fluconazole 22 0.2 9(40.9)
Others 2845 28.3 1743(61.3) 0.002
Visit type (n = 29,354)
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(PR: 0.50: 95%CI: 0.42–0.59) compared to those were on
ART (Table 2). PLHIV who received IPT at private
clinics had a 16% higher prevalence of IPT completion
compared to those in public health facilities (PR: 1.16:
95%CI: 0.99–1.36) although this was statistically non-
significant. PLHIV with WHO Stage III (PR: 1.01:
95%CI: 0.96–1.04) HIV disease had higher IPT comple-
tion compared to those with WHO Stage I. PLHIV with
WHO Stage IV (PR: 0.99: 95%CI: 0.93–1.06) HIV disease
lower six-month completion of IPT compared to those
with WHO Stage I HIV disease. PLHIV with high CD4
counts of ≥350 cells/μL had a 6% lower IPT completion
(PR: 0.94: 95%CI: 0.90–0.98) compared to those with
CD4 count < 100 cells/μL.
Multivariate multilevel analysis then adjusted for all
variables which were statistically significant at univariate
analysis or had clinical meaning or were identified a
priori as potential confounders. The variables which
were adjusted for were age, sex, year of IPT initiation,
ART status, clinical stage (important variable), CD4
counts in cells/μL and client visit status as well as ac-
counting the random effects due to specific health facil-
ity. The adjusted PR shows patients not on ART had a
46% lower IPT completion when compared to those not
on ART (APR: 0.54: 95%CI: 0.45–0.64). PLHIV who
transferred to other clinics within Dar es Salaam region
had 37% lower IPT completion compared to those were
attending in the same clinics (APR:0.63: 95%CI:0.54–
0.74). Compared to 2013 the prevalence of completing
IPT was 24% higher in 2016 (APR: 1.24: 95%CI: 1.14–
1.36) and 34% higher in 2017 (APR: 1.34: 95%: 1.22–
1.47). The IPT completion rate was 6% lower among
PLHIV aged 25–34 years compared to those aged 15 to
24 years (APR:0.94: 95%CI:0.89–0.98). The random ef-
fects results showed that 5.8% of the variability in IPT
completion was due to differences between health facil-
ities (Table 2).
Discussion
These data show the completion of IPT among PLHIV
who are attending routine HIV services in Dar-es-Salaam,
Tanzania. The overall IPT completion was 58% and it in-
creased over the 4 years from 42% in 2013 to 76% in 2017.
This probably reflects the improved HIV services provided
in the health facilities in Tanzania with better linkage be-
tween TB and HIV services, increased HIV testing and
immediate ART initiation for those testing positive [47].
Since 2013 TB and HIV services have been devolved to
lower level health facility in Tanzania [47].
Among the clients who did not complete IPT in the
recommended period of 6 months, 96.2% discontinued
IPT within the first 3 months of initiation. This is con-
sistent with findings from Malawi, Zimbabwe and
Ethiopia, which showed of those who stopped, 85, 89
and 89% respectively stopped in the first month [32, 48,
49]. Patients may be discouraged by the long treatment
duration of IPT and the need to attend clinic every
month [32, 48, 49]. Interventions have been considered
Table 1 Demographic and Clinical characteristics of 29,382 Participants Attending HIV Services in Dar es Salaam Region (Continued)
Variable Frequency % IPT completers N = 17,092(58.2) P-value
Scheduled 26,512 90.3 15,435(58.2)
Traced back after LTFU 238 0.8 161(67.7)
Treatment supported drugs pick up 287 1.0 174(60.6)
Unscheduled 2317 7.9 1309(56.5) 0.007
Fig. 2 . Trend of IPT completion prevalence by years
Robert et al. BMC Infectious Diseases          (2020) 20:276 Page 5 of 9
to help new patients in those first few months, such as
automated mobile phone short message services (SMS),
smart-phone applications and home visits by lay coun-
sellors as these have been shown to be effective in
Malawi [49].
PLHIV who were transferred to another clinics within
Dar es Salaam region after IPT initiation had signifi-
cantly lower IPT completion as compared to those
attended the same clinic for the whole 6 months. This
result is similar to the findings from Zimbabwe and
Table 2 Determinants of IPT completion among PLHIV adjust for clustering at health facilities
Variable CPR(95%CI) ICC P-value APR(95%CI) P-value ICC
Age category
15–24 0.97(0.90–1.05) 8.5% 0.439 0.97(0.89–1.04) 0.336
25–34 0.94(0.89–0.98) 0.003 0.94(0.89–0.98) 0.010
35–44 0.97(0.94–1.01) 0.091 0.97(0.94–1.01) 0.182
≥ 45 Reference Reference
Sex
Female Reference Reference
Male 1.01(0.97–1.04) 8.5% 0.710 0.99(0.96–1.03) 0.876
Years of IPT
2013 Reference Reference
2014 0.93(0.85–1.02) 0.121 0.92(0.84–1.02) 0.101
2015 0.98(0.89–1.08) 0.736 0.98(0.89–1.07) 0.621
2016 1.26(1.16–1.38) < 0.001 1.24(1.14–1.36) < 0.001




Divorced/widowed 1.01(0.96–1.05) 8.5% 0.944
Health facility ownership
Public Reference Reference
Private 1.16(0.99–1.36) 7.9% 0.067 1.11(0.97–1.26) 0.144
ARV status
On ARV Reference Reference
Not on ARV 0.50(0.42–0.59) 8.3% < 0.001 0.54(0.45–0.64) < 0.001
WHO stage
I Reference Reference
II 0.98(0.94–1.03) 0.553 0.98(0.94–1.04) 0.613
III 1.01(0.96–1.04) 0.986 0.98(0.94–1.02) 0.376
IV 0.99(0.93–1.06) 8.4% 0.907 0.97(0.91–1.04) 0.455
CD4 counts in cells/ mm3
< 100 Reference Reference
100–349 0.96(0.93–0.99) 0.022 0.97(0.94–1.01) 0.083
≥ 350 0.94(0.90–0.98) 8.5% 0.007 0.96(0.92–1.01) 0.085
Client visit status
Attending in the clinics at which client was initially
enrolled in HIV care
Reference Reference
Missing appointments 0.87(0.76–1.01) 0.068 0.88(0.76–1.02) 0.098
Transferred to another clinics within Dar es Salaam 0.63(0.60–0.71) 8.5% < 0.001 0.63(0.54–0.74) < 0.001 5.8%
Key CPR-Crude prevalence ratio, CI-Confidence interval and APR-Adjusted prevalence ratio; ICC: Intra cluster correlation
Other adjusted covariates are: functional status and visit type
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Ethiopia [27, 32]. The significantly higher IPT comple-
tion rate among PLHIV on ART is consistent with re-
sults obtained in Kenya, Zimbabwe and Brazil [30, 32,
37]. These results indicate that patients who are already
linked with ART services have an increased prevalence
of IPT completion. The significantly lower prevalence of
IPT completion among those aged 25–34 years com-
pared to those aged 15–24 years was consistent with a
study in Uganda, but contrary to the results from
Malawi [36, 49]. HIV patients with high CD4 counts
≥350 cells/μL had lower prevalence of IPT completion
compared with those with CD4 counts < 100 cells/μL.
This is consistent with studies in Kenya and Brazil [30,
37]. Possibly patients with high CD4 counts perceive
themselves healthy and not at risk of progressing to ac-
tive TB, so they stop taking IPT before completing the
full treatment course of six months.
There was non-significant lower IPT completion
among clients with advanced stage HIV disease, as
shown by PLHIV with low CD4 counts, differed from
findings from a study in Malawi [48]. PLHIV with ad-
vanced HIV stage are at higher risk of death which
would be a reason for them not completing IPT al-
though this was not statistically significant in a study in
Zimbabwe [32]. PLHIV attending private health facilities
had higher IPT completion compared to those attending
public facilities althouhg this was not significant in this
analysis. The differential might imply socio-economic in-
equities and difference in services costs between private
and public health facilities, which was shown to influ-
ence IPT completion in Jamaica and Uganda [36, 50].
Although Tanzanian guidelines for HIV services cover
both public and private facilities, more could be done to
harmonize the practice styles and skills between private
and public clinics.
The current study had strenghs due to large sample
size and high power ≥ 90% to detect the true association
between IPT completion and with its determinants. The
study used routinely collected data, which reflected the
real practices in Dar es Salaam, and the same analysis
can be incorporated into regular analyses of the CTC
data across Tanzania. The study included longer time
interval which helped to account for population changes
since IPT program was rollout in Tanzania. The study
used modified Poisson regression, with robust standard
errors, to avoid biases and to account for overdispersion.
The study accounted for the effects of health facilities by
using random effects to adjust for the clustering in the
health facility. One limitation was the incompleteness
and missing data which might have underestimated or
overestimated the estimated prevalence ratios of IPT
completion. Another limitation is that the study used
routinely collected data which are collected for patient
mangaement and programatic purposes, and not for
research puporses. Therefore some important variables
which are possibly associated with IPT completion are
not routinely collected and recorded in the CTC2
database.
Conclusions
IPT completion rate prevalence in Dar es Salaam region
was low in 2013 but increased over time. This corresponds
with a general improvement in HIV services, and the
monitoring and evaluation of HIV services in Tanzania. It
is important to maintain that increase to ensure people
living with HIV are protected against TB disease. Targeted
interventions need to be developed to assist patients with
lower IPT completion. Further analysis of routinely col-
lected health data should be done to monitor the changes
in IPT completion among PLHIV. More research is
needed on the effects of IPT non-completion rates and its
reasons among PLHIV who initiate IPT in Tanzania.
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